470 related articles for article (PubMed ID: 29252078)
1. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
2. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
3. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
4. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
5. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
7. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
11. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.
Jurado JO; Alvarez IB; Pasquinelli V; Martínez GJ; Quiroga MF; Abbate E; Musella RM; Chuluyan HE; García VE
J Immunol; 2008 Jul; 181(1):116-25. PubMed ID: 18566376
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway.
Buermann A; Römermann D; Baars W; Hundrieser J; Klempnauer J; Schwinzer R
Xenotransplantation; 2016 Sep; 23(5):347-56. PubMed ID: 27613101
[TBL] [Abstract][Full Text] [Related]
14. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
15. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
Kinter AL; Godbout EJ; McNally JP; Sereti I; Roby GA; O'Shea MA; Fauci AS
J Immunol; 2008 Nov; 181(10):6738-46. PubMed ID: 18981091
[TBL] [Abstract][Full Text] [Related]
16. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
17. PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Litak J; Mazurek M; Grochowski C; Kamieniak P; Roliński J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661771
[TBL] [Abstract][Full Text] [Related]
18. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
20. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]